Molecular pathogenesis and prognostic factors in endometrial carcinoma

APMIS

Volumn 110, Issue 10, 2002, Pages 673-689

  Salvesen, Helga B ^a   Akslen, Lars A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Endometrial cance; Molecular pathogenesis; Prognostic markers

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P16; PROTEIN P21; PROTEIN P53;

CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CLINICAL EXAMINATION; ENDOMETRIUM CARCINOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INDUSTRIALIZATION; MOLECULAR BIOLOGY; MORPHOMETRICS; PATHOGENESIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURGICAL APPROACH; TUMOR CELL;

ENDOMETRIAL NEOPLASMS; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PLOIDIES; PROGNOSIS; RECEPTORS, SOMATOTROPIN; RECEPTORS, STEROID;

EID: 0036818239     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2002.1101001.x     Document Type: Review

References (214)

1. The Cancer Registry of Norway. Cancer in Norway 1998. 1st Ed. Oslo, Norway: Institute for Epidemiological Cancer Research, 2001.
2. Mikuta JJ. International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer 1993;71:1460-3.
3. Rose PG. Endometrial carcinoma. N Eng J Med 1996;335:640-9.
4. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10.
5. Watson P, Vasen HF, Mecklin JP Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994;96:516-20.
6. Hedrick L. Endometrial cancer. In: Vogelstein B, Kinzler KW, editors. The Genetic Basis of Human Cancer. New York: McGraw-Hill, 1998:621-9.
7. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127-35.
8. Goodman MT, Hankin JH, Wilkens LR, Lyu LC, McDuffie K, Liu LQ, et al. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res 1997;57:5077-85.
9. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-6.
10. Tretli S, Magnus K. Height and weight in relation to uterine corpus cancer morbidity and mortality: A follow up study of 570,000 women in Norway. Int J Cancer 1990;46:165-72.
11. Kvåle G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: A prospective study. Cancer Res 1988;48:6217-21.
12. Albrektsen G, Heuch I, Tretli S, Kväle G. Is the risk of cancer of the corpus uteri reduced by a recent pregnancy? A prospective study of 765,756 Norwegian women. Int J Cancer 1995;61:485-90.
13. De Ward F, De Ridder CM, Baanders-van Halewyn EA, Slotboom BJ. Endometrial cancer in a cohort screened for breast cancer. Eur J Cancer Prev 1996;5:99-104.
14. Parazzini F, La Vecchia C, Negri E, Fedele L, Balotta F. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol 1991;164:522-7.
15. Santin AD, Parham GP. Routine lymph node dissection in the treatment of early stage cancer: Are we doing the right thing? Gynecol Oncol 1998;68:1-3.
16. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
17. Candiani GB, Belloni C, Maggi R, Colombo G, Frigoli A, Carinelli SG. Evaluation of different surgical approaches in the treatment of endometrial cancer at FIGO stage I. Gynecol Oncol 1990;37:6-8.
18. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F, et al. Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:29-33.
19. Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998;71:340-3.
20. Larson DM, Johnson K, Olson KA. Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer: Morbidity and mortality. Obstet Gynecol 1992;79:998-1001.
21. Corn BW, Lanciano RM, Greven KM, Noumoff J, Schultz D, Hanks GE, et al. Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: A multivariate analysis. J Clin Oncol 1994;12:510-5.
22. Gretz HF, Economos K, Husain A, Lesser M, Kaplan E, Caputo TA, et al. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol 1996;61:409-15.
23. Aalders J, Abeler V, Kolstad P, Onsrud M. Post-operative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419-27.
24. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radio-therapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-11.
25. Maggino T, Romagnolo C, Zola P, Sartori E, Landoni F, Gadducci A. An analysis of approaches to the treatment of endometrial cancer in Western Europe: A CTF study. Eur J Cancer 1995;31A:1993-7.
26. Vergote I, Kjørstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64:1011-6.
27. Martin-Hirsch PL, Lilford RJ, Jarvis GJ. Adjuvant progestagen therapy for the treatment of endometrial cancer: Review and recta-analyses of published randomised controlled trials. Eur J Obstet Gynecol Reprod Biol 1996;65:201-7.
28. Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow up of patients treated for endometrial carcinoma. Gynecol Oncol 1994;55:229-33.
29. Owen P, Duncan ID. Is there any value in the long term follow up of women treated for endometrial carcinoma? Br J Obstet Gynaecol 1996;103:710-3.
30. Greven K, Olds W. Isolated vaginal recurrences of endometrial adenocarcinoma and their management. Cancer 1987;60:419-21.
31. Podczaski E, Kaminski P, Gurski K, MacNeill C, Stryker JA, Singapuri K, et al. Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. Gynecol Oncol 1992;47:323-7.
32. Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions. J Clin Oncol 1991;9:1071-88.
33. Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 1997;104:1302-7.
34. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Cancer. Molecular Biology of the Cell. New York: Garland Publishing, Inc., 1994:1255-94.
35. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995;76:2034-40.
36. Caduff RF, Svoboda-Neumann SM, Johnston CM, Bartos RE, Frank TS. Molecular analysis in endometrial cancer. Verh Dtsch Ges Pathol 1997;81:219-27.
37. Berchuck A. Biomarkers in the endometrium. J Cell Biochem 1995;23:174-8.
38. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
39. Jacks T, Weinberg A. Cell-cycle control and its watchman. Nature 1996;381:643-4.
40. Kinzler KW, Vogelstein B. Life (and death) in a malignant tumour. Nature 1996;379:19-20.
41. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
42. Kirsch DG, Kastan MB. Tumor-suppressor p53: Implications for tumor development and prognosis. J Clin Oncol 1998;16:3158-68.
43. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
44. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998;17:2413-7.
45. Wijnen J, Leeuw W, Vasen H, Klift H, Moller P, Stormorken A, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999;23:142-4.
46. Niederacher D, An HX, Cho YJ, Hantschmann P, Bender HG, Beckmann MW. Mutations and amplification of oncogenes in endometrial cancer. Oncology 1999;56:59-65.
47. Boyd J, Risinger JI. Analysis of oncogene alterations in human endometrial carcinoma: Prevalence of ras mutations. Mol Carcinog 1991;4:189-95.
48. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001;91:22-6.
49. Salvesen HB, MacDonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000;6:3607-13.
50. MacDonald ND, Salvesen HB, Ryan A, Iversen OE, Akslen LA, Jacobs IJ. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 2000;60:1750-2.
51. Koul A, Willen R, Bendahl PO, Nilbert M, Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 2002;94:2369-79.
52. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 1999;59:462-6.
53. Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996;148:1671-8.
54. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999;8:661-6.
55. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. Eur J Cancer 1997;33:1572-7.
56. Varras MN, Koffa M, Koumantakis E, Ergazaki M, Protopapa E, Michalas S, et al. Ras gene mutations in human endometrial carcinoma. Oncology 1996;53:505-10.
57. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, et al. Over-expression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.
58. Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: Correlation with overall survival. Cancer Res 1995;55:5693-8.
59. Risinger JI, Dent GA, Ignar-Trowbridge D, McLachlan JA, Tsao MS, Senterman M, et al. p53 gene mutations in human endometrial carcinoma. Mol Carcinog 1992;5:250-3.
60. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996;74:562-7.
61. Kihana T, Hamada K, Inoue Y, Yano N, Iketani H, Murao S, et al. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Cancer 1995;76:72-8.
62. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996;27:1050-5.
63. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85:729-34.
64. Strang P, Nordström B, Nilsson S, Bergström R, Tribukait B. Mutant p53 protein as a predictor of survival in endometrial carcinoma. Eur J Cancer 1996;32A:598-602.
65. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-52.
66. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
67. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53 and p21 expression: A population-based endometrial carcinoma study. J Clin Oncol 1999;17:1382-90.
68. Ito K, Sasano H, Matsunaga G, Sato S, Yajima A, Nasim S, et al. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997;183:318-24.
69. Palazzo JP, Mercer WE, Kovatich AJ, McHugh M. Immunohistochemical localization of p21 (WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 1997;28:60-6.
70. Wong YF, Chung TK, Cheung TH, Nobori T, Yim SF, Lai KW, et al. p161NK4 and p15INK4B alterations in primary gynecologic malignancy. Gynecol Oncol 1997;65:319-24.
71. Peiffer SL, Bartsch D, Whelan AJ, Mutch DG, Herzog TJ, Goodfellow PJ. Low frequency of CDKN2 mutation in endometrial carcinomas. Mol Carcinog 1995;13:210-2.
72. Hatta Y, Hirama T, Takeuchi S, Lee E, Pham E, Miller CW, et al. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol 1995;154:1954-7.
73. Milde-Langosch K, Riethdorf L, Bamberger AM, Löning T. P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch 1999;434:23-8.
74. Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 1997;80:2250-6.
75. Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K, Wada H, et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 1999;80:458-67.
76. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000;6:153-9.
77. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-7.
78. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
79. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-10.
80. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
81. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
82. Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 1995;55:1922-6.
83. Salvesen HB, Stefansson I, Kalvenes MB, Das S, Akslen LA. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2002;94:2185-91.
84. Peltomäki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997;113:1146-58.
85. Katabuchi H, van Rees B, Lambers AR, Ronnett BM, Blazes MS, Leach FS, et al. Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 1995;55:5556-60.
86. Kowalski LD, Mutch DG, Herzog TJ, Rader JS, Goodfellow PJ. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer 1997;18:219-27.
87. Stefansson I, Akslen LA, MacDonald N, Ryan A, Das S, Jacobs IJ, et al. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: A population-based study. Clin Cancer Res 2002;8:138-43.
88. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
89. Knudson AG. Hereditary cancer: Two hits revisited. J Cancer Res Clin Oncol 1996;122:135-40.
90. Vogelstein B, Kinzler KW. The Genetic Basis of Human Cancer. 1st Ed. New York: McGraw-Hill, 1998.
91. Okamoto A, Sameshima Y, Yamada Y, Teshima S, Terashima Y, Terada M, et al. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 1991;51:5632-5.
92. Gima T, Kato H, Honda T, Imamura T, Sasazuki T, Wake N. DCC gene alteration in human endometrial carcinomas. Int J Cancer 1994;57:480-5.
93. Fujino T, Risinger JI, Collins NK, Liu FS, Nishii H, Takahashi H, et al. Allelotype of endometrial carcinoma. Cancer Res 1994;54:4294-8.
94. Baylin SB, Herman JG, Graft JR, Vertino PM, Issa JR Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
95. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
96. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
97. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
98. Press ME Greene GL. Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology 1988;122:1165-75.
99. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796-807.
100. Navari JR, Roland PY, Keh P, Salvesen HB, Akslen LA, Iversen OE, et al. Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5′ end of the ER gene. Clin Cancer Res 2000;6:4026-32.
101. Murphy LJ, Gong Y, Murphy LC, Bhavnani B. Growth factors in normal and malignant uterine tissue. Ann N Y Acad Sci 1991;622:383-91.
102. Anzai Y, Gong Y, Holinka CF, Murphy LJ, Murphy LC, Kuramoto H, et al. Effects of transforming growth factors and regulation of their mRNA levels in two human endometrial adenocarcinoma cell lines. J Steroid Biochem Mol Biol 1992;42:449-55.
103. Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-7.
104. Boyd JA, Kaufman DG. Expression of transforming growth factor beta 1 by human endometrial carcinoma cell lines: Inverse correlation with effects on growth rate and morphology. Cancer Res 1990;50:3394-9.
105. Gold LI, Saxena B, Mittal KR, Marmor M, Goswami S, Nactigal L, et al. Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: Evidence for paracrine and autocrine action. Cancer Res 1994;54:2347-58.
106. Bamberger AM, Bamberger CM, Schulte HM. Molecular mechanisms of proliferation in endometrial tumour cells. Hum Reprod Update 1998;4:526-31.
107. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, et al. K-ras point mutations in endometrial carcinoma: Effect on outcome is dependent on age of patient. Gynecol Oncol 1996;63:238-46.
108. Duggan BD, Felix JC, Muderspach LI, Tsao JL, Shibata DK. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res 1994;54:1604-7.
109. Al-Jehani RM, Jeyarajah AR, Hagen B, Hogdall EV, Oram DH, Jacobs IJ. Model for the molecular genetic diagnosis of endometrial cancer using K- ras mutation analysis. J Natl Cancer Inst 1998;90:540-2.
110. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
111. Helland A, Børresen-Dale AL, Peltomäki P, Hektoen M, Kristensen GB, Nesland JM, et al. Microsatellite instability in cervical and endometrial carcinomas. Int J Cancer 1997;70:499-501.
112. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100-3.
113. Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J, Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994;86:1216-21.
114. Nagase S, Sato S, Tezuka F, Wada Y, Yajima A, Horii A. Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. Br J Cancer 1996;74:1979-83.
115. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
116. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614-7.
117. Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H, et al. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res 2001;61:3741-9.
118. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000.
119. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30.
120. Battifora H. p53 immunohistochemistry: A word of caution. Hum Pathol 1994;25:435-7.
121. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
122. Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen AL. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 1997;181:140-5.
123. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 1991 ;324:1-8.
124. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
125. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenetic switch during tumorigenesis. Cell 1996;86:353-64.
126. Straume O, Akslen LA. Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001;159:223-35.
127. Zachary I. Vascular endothelial growth factor. Int J Biochem Cell Biol 1998;30:1169-74.
128. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861-5.
129. Salvesen HB, Akslen LA. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 1999;84:538-43.
130. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, et al. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219-27.
131. Guo N, Zabrenetzky VS, Chandrasekaran L, Sipes JM, Lawler J, Krutzsch HC, et al. Differential roles of protein kinase C and pertussis toxin-sensitive G- binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1. Cancer Res 1998;58:3154-62.
132. Joseph IB, Isaacs JT. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 1998;90:1648-53.
133. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-9.
134. Abeler VM, Kjørstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991;67:3093-103.
135. Iversen OE. Flow cytometric deoxyribonucleic acid index: A prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 1986;155:770-6.
136. Connelly PJ, Alberhasky RC, Christopherson WM. Carcinoma of the endometrium. III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 1982;59:569-75.
137. Zaino R, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial carcinoma. Cancer 1996;77:1115-21.
138. Britton LC, Wilson TO, Gaffey TA, Lieber MM, Wieand HS, Podratz KC. Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol Oncol 1989;34:317-22.
139. FIGO (International Federation of Gynecology and Obstetrics). FIGO stages, 1988 revision. Gynecol Oncol 1989;35:125-7.
140. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
141. Abeler VM, Kjørstad KE. Clear cell carcinoma of the endometrium: A histopathological and clinical study of 97 cases. Gynecol Oncol 1991;40:207-17.
142. Abeler VM, Kjørstad KE. Serous papillary carcinoma of the endometrium: A histopathological study of 22 cases. Gynecol Oncol 1990;39:266-71.
143. Carriaga MT, Henson DE. The histologic grading of cancer. Cancer 1995;75:406-21.
144. Mittal KR, Schwartz PE, Barwick KW. Architectural (FIGO) grading, nuclear grading, and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high risk and low risk groups. Cancer 1988;61:538-45.
145. Zaino RJ, Silverberg SG, Norris HJ, Bundy BN, Morrow CP, Okagagi T. The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma: A gynecologic oncology group study. Int J Gynecol Pathol 1994;13:29-36.
146. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological typing of female genital tract tumours. International Histological Classification of Tumours. 2nd Ed. Berlin Heidelberg: World Health Organization, Springer-Verlag, 1994.
147. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000;24:1201-8.
148. Baak JPA. Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. 1st Ed. Berlin, Heidelberg, Springer-Verlag, 1991.
149. Van der Putten HWHM, Baak JPA, Koenders TJM, Kurver PH, Stolk HG, Stolte LAM. Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer 1989;63:1378-87.
150. Sorbe B, Risberg B, Thornthwaite J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer 1994;4:94-100.
151. Salvesen HB, Iversen OE, Akslen LA. Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer 1998;83:956-64.
152. Creasman WT Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993;71:1467-70.
153. Nyholm HC, Christensen IJ, Nielsen AL. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 1995;59:347-51.
154. Iversen OE, Utaaker E, Skaarland E. DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1988;67:531-7.
155. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-5.
156. Geisler JP, Wiemann MC, Zhou Z, Miller GA, Geisler HE. P53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 1996;61:245-8.
157. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85.
158. Thornton JG, Ali S, O'Donovan P, Griffin N, Wells M, MacDonald RR. Flow cytometric studies of ploidy and proliferative indices in the Yorkshire trial of adjuvant progestogen treatment of endometrial cancer. Br J Obstet Gynaecol 1993;100:253-61.
159. Jacobsen M, Jakobsen A, Nedergaard L, Andersen JE, Nielsen K. Endometrial carcinomas - Flow cytometric DNA content and S-phase values. Pathol Res Pract 1997;193:283-90.
160. Moberger B, Auer G, Forsslund G, Moberger G. The prognostic significance of DNA measurements in endometrial carcinoma. Cytometry 1984;5:430-6.
161. Larson DM, Berg R, Shaw G, Krawisz BR. Prognostic significance of DNA ploidy in endometrial cancer. Gynecol Oncol 1999;74:356-60.
162. Kodama S, Kase H, Tanaka K, Matsui K. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet 1996;53:23-30.
163. Salvesen HB, Iversen OE, Akslen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 1998;4:2779-85.
164. Atkin NB. Prognostic significance of ploidy level in human tumors. I. Carcinoma of the uterus. J Natl Cancer Inst 1976;56:909-10.
165. Geisinger KR, Homesley HD, Morgan TM, Kute TE, Marshall RB. Endometrial adenocarcinoma. A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer 1986;58:1518-25.
166. Lindahl B, Alm P, Killander D, Langstrom E, Trope C. Flow cytometric DNA analysis of normal and cancerous human endometrium and cytological-histopathological correlations. Anticancer Res 1987;7:781-9.
167. Quillamor RM, Furlong JW, Hoschner JA, Wynn RM. Relative prognostic significance of DNA flow cytometry and histologic grading in endometrial carcinoma. Gynecol Obstet Invest 1988;26:332-7.
168. Rosenberg P, Wingren S, Simonsen E, Stal O, Risberg B, Nordenskjold B. Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: An important prognostic indicator. Gynecol Oncol 1989;35:50-4.
169. Newbury R, Schuerch C, Goodspeed N, Fanning J, Glidewell O, Evans M. DNA content as a prognostic factor in endometrial carcinoma. Obstet Gynecol 1990;76:251-7.
170. Britton LC, Wilson TO, Gaffey TA, Cha SS, Wieand HS, Podratz KC. DNA ploidy in endometrial carcinoma: Major objective prognostic factor. Mayo Clin Proc 1990;65:643-50.
171. Stendahl U, Strang P, Wagenius G, Bergstrom R, Tribukait B. Prognostic significance of proliferation in endometrial adenocarcinomas: A multivariate analysis of clinical and flow cytometric variables. Int J Gynecol Pathol 1991;10:271-84.
172. Ambros RA, Kurman RJ. Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol 1992;45:235-9.
173. Dyas CH, Simmons TK, Ellis CN, Austin JM Jr, Partridge EE Jr, Kilgore LC, et al. Effect of deoxyribonucleic acid ploidy status on survival of patients with carcinoma of the endometrium. Surg Gynecol Obstet 1992;174:133-6.
174. Wagenius G, Bergström R, Strang P, Gerdes U, Rogo K, Tribukait B, et al. Prognostic significance of flow cytometric and clinical variables in endometrial adenocarcinoma stages I and II. Anticancer Res 1992;12:725-32.
175. Goodman A, Bell DA, Rice LW. DNA ploidy status: Its impact on early-stage endometrial adenocarcinoma. Gynecol Oncol 1993;51:355-61.
176. Podratz KC, Wilson TO, Gaffey TA, Cha SS, Katzmann JA. Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients. Am J Obstet Gynecol 1993;168:1206-15.
177. Ikeda M, Watanabe Y, Nanjoh T, Noda K. Evaluation of DNA ploidy in endometrial cancer. Gynecol Oncol 1993;50:25-9.
178. Susini T, Rapi S, Savino L, Boddi V, Berti P, Massi G. Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial
179. Lindahl B, Ranstam J, Willen R. Five year survival rate in endometrial carcinoma stages I-II: Influence of degree of tumour differentiation, age, myometrial invasion and DNA content. Br J Obstet Gynaecol 1994;101:621-5.
180. Friberg LG, Noren H, Delle U. Prognostic value of DNA ploidy and S-phase fraction in endometrial cancer stage I and II: A prospective 5-year survival study. Gynecol Oncol 1994;53:64-9.
181. Gudmundsson TE, Langstrom E, Alm P, Anderson H, Baldetorp B, Ferno M, et al. Methodological aspects of flow cytometry DNA analysis in endometrial carcinoma, with special reference to sampling and reproducibility. Acta Oncol 1996;35:999-1006.
182. Lindahl B, Ranstam J, Norgren A, Willen R. Identification of high-risk groups in endometrial carcinoma stage I-II. A combination of DNA- and steroid receptor- measurements identifies early deaths from the disease. Anticancer Res 1995;15:1095-100.
183. Pfisterer J, Kommoss F, Sauerbrei W, Rendl I, Kiechle M, Kleine W, et al. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. Gynecol Oncol 1995;58:149-56.
184. Nazeer T, Ballouk E Malfetano JH, Figge H, Ambros RA. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. Am J Obstet Gynecol 1995;173:1829-34.
185. Nordström B, Strang P, Lindgren A, Bergström R, Tribukait B. Endometrial carcinoma: The prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Anticancer Res 1996;16:899-904.
186. Nordström B, Strang P, Bergström R, Nilsson S, Tribukait B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Cancer 1996;78:1942-51.
187. Zaino RJ, Davis AT, Ohlsson-Wilhelm BM, Brunetto VL. DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int J Gynecol Pathol 1998;17:312-9.
188. Salvesen HB, Akslen LA, Albrektsen G, Iversen OE. Poorer survival for nulliparous women with endometrial carcinoma. Cancer 1998;82:1328-33.
189. Hachisuga T, Fukuda K, Hirakawa T, Kawarabayashi T. The effect of nulliparity on survival in endometrial cancer at different ages. Gynecol Oncol 2001;82:122-6.
190. Hall PA, Woods AL. Immunohistochemical markers of cellular proliferation: Achievements, problems and prospects. Cell Tissue Kinet 1990;23:505-22.
191. Bowen ID, Bowen SM, Jones A. Mitosis and Apoptosis. 1st Ed. London: Chapman & Hall, 1998.
192. van Diest PJ, Brugal G, Baak JP. Proliferation markers in tumours: Interpretation and clinical value. J Clin Pathol 1998;51:716-24.
193. Kaleli S, Kosebay D, Bese T, Demirkiran F, Oz UA, Arvas M, et al. A strong prognostic variable in endometrial carcinoma: Flow cytometric S-phase fraction. Cancer 1997;79:944-51.
194. Geisler JP, Wiemann MC, Zhou Z, Miller GA, Geisler HE. Proliferation index determined by MIB-1 and recurrence in endometrial cancer. Gynecol Oncol 1996;61:373-7.
195. Gassel AM, Backe J, Krebs S, Schon S, Caffier H, Muller-Hermelink HK. Endometrial carcinoma: Immunohistochemically detected proliferation index is a prognosticator of long-term outcome. J Clin Pathol 1998;51:25-9.
196. Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 1995;86:479-85.
197. Kirschner CV, Alanis-Amezcua JM, Martin VG, Luna N, Morgan E, Yang JJ, et al. Angiogenesis factor in endometrial carcinoma: A new prognostic indicator? Am J Obstet Gynecol 1996;174:1879-84.
198. Kaku T, Kamura T, Kinukawa N, Kobayashi H, Sakai K, Tsuruchi N, et al. Angiogenesis in endometrial carcinoma. Cancer 1997;80:741-7.
199. Salvesen HB, Iversen OE, Akslen LA. Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer 1998;77:1140-4.
200. Abulafia O, Sherer DM. Angiogenesis of the endometrium. Obstet Gynecol 1999;94:148-53.
201. Bigsby RM, Li AX, Bomalaski J, Stehman FB, Look KY, Sutton GP. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 1992;79:95-100.
202. Wang D, Konishi I, Koshiyama M, Mandai M, Nanbu Y, Ishikawa Y, et al. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status. Cancer 1993;72:2628-37.
203. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-83.
204. Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992;52:2777-81.
205. Moll UM, Chalas E, Auguste M, Meaney D, Chumas J. Uterine papillary serous carcinoma evolves via a p53 driven pathway. Hum Pathol 1996;27:1295-300.
206. Tashoiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. P53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
207. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki67, estrogen, and progesterone receptor expression. Hum Pathol 1998;29:551-8.
208. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54:4667-70.
209. Inoue M, Okayama A, Fujita M, Enomoto T, Sakata M, Tanizawa O, et al. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer 1994;58:14-9.
210. Jones MW, Kounelis S, Hsu C, Papadaki H, Bakker A, Swalsky PA, et al. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: A clinicopathologic and molecular comparison. Int J Gynecol Pathol 1997;16:354-60.
211. Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature - a potential therapeutic target. Br J Cancer 1995;72:257-67.
212. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8.
213. Maekawa R, Maki H, Yoshida H, Hojo K, Tanaka H, Wada T, et al. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res 1999;59:1231-5.
214. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998;95:8795-800.